相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Classifying PML risk with disease modifying therapies
Joseph R. Berger
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Natalizumab-PML survivors with subsequent MS treatment
Elisabeth Maillart et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
Simona Malucchi et al.
NEUROLOGY AND THERAPY (2017)
Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail
Jeroen Van Schependom et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Jens Ingwersen et al.
NEUROTHERAPEUTICS (2016)
Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail
Jeroen Van Schependom et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
Per Soelberg Sorensen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials
Lei Diao et al.
CLINICAL PHARMACOKINETICS (2016)
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Harold L. Atkins et al.
LANCET (2016)
Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications
Giordani Rodrigues Dos Passos et al.
MEDIATORS OF INFLAMMATION (2016)
The challenge of comorbidity in clinical trials for multiple sclerosis
Ruth Ann Marrie et al.
NEUROLOGY (2016)
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
A. L. Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
Horst Penkert et al.
JAMA NEUROLOGY (2016)
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
Stacy Ellen Hatcher et al.
JAMA NEUROLOGY (2016)
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
Giancarlo Comi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Brain health: time matters in multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS Patient management considerations
Robert J. Fox et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS
Tim Spelman et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
Defining high, medium and low impact prognostic factors for developing multiple sclerosis
Mar Tintore et al.
BRAIN (2015)
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation
Benjamin Berger et al.
JOURNAL OF NEUROIMMUNOLOGY (2015)
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis
Gaspard Gerschenfeld et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Autologous hematopoietic stem cell transplantation in multiple sclerosis A phase II trial
Giovanni L. Mancardi et al.
NEUROLOGY (2015)
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
Ludwig Kappos et al.
NEUROLOGY (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
L. Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Thorsten Rosenkranz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) A 3-Year Interim Report
Richard A. Nash et al.
JAMA NEUROLOGY (2015)
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Dalia L. Rotstein et al.
JAMA NEUROLOGY (2015)
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis
Gaspard Gerschenfeld et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS)
Sura Alwan et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Optimizing therapy early in multiple sclerosis: An evidence-based view
Tjalf Ziemssen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
Roberto Bomprezzi
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Alberto Gajofatto et al.
WORLD JOURNAL OF CLINICAL CASES (2015)
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade
David J. Huss et al.
JOURNAL OF IMMUNOLOGY (2015)
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
Michael Kaufman et al.
JOURNAL OF NEUROLOGY (2015)
Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model
Martin Stangel et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
Vissia Viglietta et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study
J. Theodore Phillips et al.
NEUROLOGY AND THERAPY (2015)
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
Rachel Babij et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2015)
Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
Collin M. Spencer et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
FATAL ACUTE LIVER FAILURE WITH HEPATITIS B VIRUS INFECTION DURING NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS
Machteld E. Hillen et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
Alberto Gajofatto et al.
DRUG HEALTHCARE AND PATIENT SAFETY (2015)
Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Tatiana Plavina et al.
ANNALS OF NEUROLOGY (2014)
Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis
Renaud A. Du Pasquier et al.
CNS DRUGS (2014)
New management algorithms in multiple sclerosis
Per Soelberg Sorensen
CURRENT OPINION IN NEUROLOGY (2014)
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Amit Bar-Or et al.
DRUGS (2014)
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis
Gilbert H. Daniels et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
Gavin Giovannoni et al.
JOURNAL OF NEUROLOGY (2014)
Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study
Cecilie Jacobsen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis
Michael Kaufman et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
Gavin Giovannoni et al.
LANCET NEUROLOGY (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study
L. Lavorgna et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G. Francis et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Natalizumab to fingolimod washout in patients at risk of PML When good intentions yield bad outcomes
Gavin Giovannoni et al.
NEUROLOGY (2014)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study)
Marinella Clerico et al.
JAMA NEUROLOGY (2014)
Switching From Natalizumab to Fingolimod in Multiple Sclerosis A French Prospective Study
Mikael Cohen et al.
JAMA NEUROLOGY (2014)
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Ron Milo
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
Claudio Gobbi et al.
BMC NEUROLOGY (2013)
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations
Mark S. Freedman et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2013)
Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
Gilles Edan et al.
CNS DRUGS (2013)
Brain atrophy and lesion load predict long term disability in multiple sclerosis
Veronica Popescu et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Ralf Gold et al.
LANCET (2013)
Scoring treatment response in patients with relapsing multiple sclerosis
M. P. Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Epigenetic changes in patients with multiple sclerosis
Marcus W. Koch et al.
NATURE REVIEWS NEUROLOGY (2013)
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis
Heinz Wiendl et al.
NATURE REVIEWS NEUROLOGY (2013)
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
Mark D. Cossburn et al.
NEUROLOGY (2013)
Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
Amit Bar-Or et al.
NEUROLOGY (2013)
Daclizumab Therapy for Multiple Sclerosis
Bibiana Bielekova
NEUROTHERAPEUTICS (2013)
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action
Kavitha Damal et al.
BIOLOGICS-TARGETS & THERAPY (2013)
Mitoxantrone for multiple sclerosis
Filippo Martinelli Boneschi et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
New Disease-Modifying Therapies and New Challenges for MS
Vijayshree Yadav et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)
A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
Xiao Hu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
Grant A. Hill-Cawthorne et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
A. J. Coles et al.
NEUROLOGY (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis
Justin S. A. Perry et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
Douglas S. Goodin et al.
BMJ OPEN (2012)
Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway
Robert H. Scannevin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?
Amy E. Lovett-Racke et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
V. Devonshire et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis Patients
Trina A. Johnson et al.
JOURNAL OF IMMUNOLOGY (2011)
Natalizumab and HSV meningitis
Erica Seiguer Shenoy et al.
JOURNAL OF NEUROVIROLOGY (2011)
Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
A. Kerbrat et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM
Patrizia Sola et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer et al.
NATURE (2011)
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
M. Cossburn et al.
NEUROLOGY (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Glatiramer Acetate Treatment Directly Targets CD11b+Ly6G- Monocytes and Enhances the Suppression of Autoreactive T cells in Experimental Autoimmune Encephalomyelitis
A. Toker et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2011)
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
Bernard Uitdehaag et al.
Therapeutic Advances in Neurological Disorders (2011)
Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex Disease
Giulio Disanto et al.
AUTOIMMUNE DISEASES (2011)
The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
Antonio Scalfari et al.
BRAIN (2010)
Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis A Non-Experimental, Retrospective, Cohort Study
Stephanie C. Steinberg et al.
CLINICAL DRUG INVESTIGATION (2010)
Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients
Trina A. Johnson et al.
CLINICAL IMMUNOLOGY (2010)
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Sara A. J. Thompson et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells
Jayne F. Martin et al.
JOURNAL OF IMMUNOLOGY (2010)
Neurofilament light as a prognostic marker in multiple sclerosis
Jonatan Salzer et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis
Robert C. Axtell et al.
NATURE MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New approaches in the management of multiple sclerosis
Laurie J. Barten et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2010)
Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
Bibiana Bielekova et al.
ARCHIVES OF NEUROLOGY (2009)
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command
Mark S. Freedman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Measures in the first year of therapy predict the response to interferon β in MS
J. Rio et al.
MULTIPLE SCLEROSIS (2009)
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks
Luciano Rinaldi et al.
NEUROLOGICAL SCIENCES (2009)
Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures
E. M. Mowry et al.
NEUROLOGY (2009)
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
B. O. Khatri et al.
NEUROLOGY (2009)
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS
Douglas L. Arnold et al.
JOURNAL OF NEUROLOGY (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
T. Vollmer et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
Christine Lebrun et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers
Iris Grossman et al.
PHARMACOGENETICS AND GENOMICS (2007)
Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis
Maria Pia Amato et al.
ARCHIVES OF NEUROLOGY (2007)
Quality assessment in multiple sclerosis therapy (QUASIMS) - A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis
Volker Limmroth et al.
JOURNAL OF NEUROLOGY (2007)
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis - A systematic review
Annette Langer-Gould et al.
ARCHIVES OF NEUROLOGY (2006)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide -: Involvement of impaired integrin activation and immunologic synapse formation
M Zeyda et al.
ARTHRITIS AND RHEUMATISM (2005)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10
J Gbadamosi et al.
EUROPEAN NEUROLOGY (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
Medical progress: Multiple sclerosis.
JH Noseworthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
